- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05283304
Monthly Injectable BUP for MA Use Disorder (MURB) Trial (CTN-0110)
Randomized, Double-blind, Placebo-controlled Trial of Monthly Injectable Buprenorphine (BUP) for Methamphetamine (MA) Use Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective: To evaluate whether assignment to 12 weeks of outpatient BUP-Inj compared to 12 weeks of outpatient PBO-Inj reduces MA use (as measured by twice-weekly urine drug screens (UDS)) during Weeks 9-12 in participants with moderate to severe MUD with co-occurring mild opioid use disorder (OUD) or opioid misuse not warranting medication for opioid use disorder (MOUD).
Secondary Objectives: To evaluate whether assignment to 12 weeks of outpatient BUP-Inj compared to 12 weeks of outpatient PBO-Inj among participants with moderate to severe MUD with co-occurring mild OUD or opioid misuse not warranting MOUD improves: 1) outcomes related to alternate measures of MA use including total number of MA negative urine drug screens (UDS) during study and self-reported days of MA use; 2) measures of opioid use and self-reported frequency of opioid use; and 3) measures of MA and opioid co-use and self-reported days of MA and opioid co-use.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90038
- UCLA Vine Street Clinic
-
Oakland, California, United States, 94602
- Highland Hospital, Alameda Health System
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74107
- Oklahoma State University, Center for Health Sciences
-
-
Oregon
-
Portland, Oregon, United States, 97214
- CODA
-
-
Texas
-
Dallas, Texas, United States, 75247
- UTSW Medical Center, Center for Depression Research and Clinical Care
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington Medicine-Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Study participants must:
- Be 18 to 65 years of age, inclusive;
- Able to understand and speak English or Spanish
- Be interested in reducing or stopping MA use;
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for moderate or severe MUD (4 or more criteria);
- Self-report MA use on 18 or more days in the 30-day period prior to written consent using the TLFB;
- Provide at least 2 urine samples positive for MA out of a possible 3 tests to occur at clinic visits within a 10-day period with at least 2 days between visits;
- Meet DSM-5 criteria for mild OUD (at least 2 but no more than 3 criteria) prior to randomization OR opioid misuse demonstrated by self-report of opioid use of at least 2 days in the 30-day period prior to written consent using the TLFB;
- Provide a urine drug screen negative for opioids at least once during the screening period and on the day of expected randomization to indicate control over opioid use;
- Have a Clinical Opiate Withdrawal Scale (COWS) score of ≤8 at both a screening visit on which they provide a UDS negative for opioids and on the day of randomization.
- If female, agree to use acceptable methods of contraception and have periodic urine pregnancy testing during participation in the study unless unable to get pregnant;
- Be willing and able to provide consent and comply with all study procedures and medication instructions.
Exclusion Criteria:
Study participants must not:
- Have suicidal or homicidal ideation that requires immediate attention;
- Have evidence of prolongation of the corrected QT interval (QTc) or any other finding on the screening ECG that, in the opinion of the Medical Clinician, would preclude safe participation in the study (e.g., hypokalemia, unstable atrial fibrillation) and be at significant risk for serious cardiac adverse events;
- Have a laboratory value with total bilirubin ≥1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) ≥3 × ULN, aspartate aminotransferase (AST) ≥5 × ULN, or serum creatinine >2 × ULN;
- Have been in a study of pharmacological or behavioral treatment for addiction within 6 months prior to written study consent (smoking cessation excepted);
- Have taken an investigational drug in another study within 30 days prior to written study consent;
- Have been prescribed and taken buprenorphine or methadone within 30 days prior to written study consent;
- Be concurrently enrolled in formal behavioral or pharmacological addiction treatment services at the time of written consent;
- Be receiving ongoing treatment of medications that are clinically relevant Cytochrome P450 3A4 (CYP 3A4) or Cytochrome P4502C8 (CYP 2C8) inducers or inhibitors (e.g., rifampicin, azole antifungals, macrolide antibiotics), Class IA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone) at the time of randomization that, in the judgment of the Medical Clinician, could interact adversely with study medications or put them at significant risk for development of serotonin syndrome;
- Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the Medical Clinician;
- Have a surgery planned or scheduled, or other treatment that would require the use of opioid-containing medications (e.g., opioid analgesics) during the study period;
- Currently or soon to be in jail or prison; currently in any inpatient overnight facility as required by court of law or have pending legal action or other situation that could prevent participation in the study or in any study activities;
- If biologically female, be currently pregnant, breastfeeding, or planning on conception;
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine or any component of the ATRIGEL formulation or their excipients;
- Have an abdominal area unsuitable for subcutaneous injections by the judgment of the Medical Clinician;
- Have other medical, psychiatric or other factors that in the judgment of the Medical Clinician could make participation difficult or unsafe.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Injectable Buprenorphine (BUP-inj)
Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable buprenorphine (300 mg dose) every 4 weeks
|
Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
Other Names:
|
Placebo Comparator: Injectable Placebo (PBO-inj)
Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable placebo (300 mg dose) every 4 weeks.
|
Sublingual buprenorphine induction, then Placebo injectable (300 mg)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of MA-negative UDS results obtained
Time Frame: week 12
|
Number of Methamphetamine (MA)-negative Urine Drug Screen (UDS) results obtained during Weeks 9 through 12 of the medication phase is measured for the BUP-Inj and PBO-Inj conditions.
|
week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Effective Score (TES) for MA-negative UDS results
Time Frame: week 12
|
The TES is defined to be the number of MA negative UDS divided by the number of possible UDS collected during the study.
In this study there are 24 possible UDS collections so the number of MA negative UDS is divided by 24.
Possible score ranges from 0-24; with higher score indicating better outcome.
|
week 12
|
Number of days of methamphetamine use during the medication phase
Time Frame: week 12
|
Number of days of methamphetamine use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported use during Weeks 1-12.
Possible scores range from 0-84, with lower scores indicating better outcome.
|
week 12
|
Treatment Effective Score (TES) for opioid negative UDS results
Time Frame: week 12
|
The TES is defined to be the number of UDS results negative for opioids divided by the number of possible UDS collected during the study.
In this study there are 24 possible UDS collections, so the number of opioid negative UDS is divided by 24.
Possible score ranges from 0-24; with higher score indicating better outcome.
|
week 12
|
Number of days of opioid use during the medication phase
Time Frame: week 12
|
Number of days of opioid use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported opioid use at week 12. Possible scores range from 0-84, with lower scores indicating better outcome.
|
week 12
|
Treatment Effective Score (TES) for MA and opioid Co-Use compiled
Time Frame: week 12
|
The TES is defined to be the number of MA and Opioid Co-Use negative UDS divided by the number of possible UDS collected during the study.
In this study there are 24 possible UDS collections, so the number of MA and Opioid Co-Use negative UDS is divided by 24.
Possible score ranges from 0-24; with higher score indicating better outcome.
|
week 12
|
Number of days of MA and opioid co-use during the medication phase
Time Frame: week 12
|
Number of days of MA and opioid co-use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported use of substances for each day at week 12. Possible scores range from 0-84, with lower scores indicating better outcome.
|
week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Madhukar Trivedi, MD, UT Southwestern Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIDA CTN Protocol 0110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine-dependence
-
University of California, Los AngelesCompletedMethamphetamine Dependence in Remission | Continuous Methamphetamine Dependence
-
National Institute on Drug Abuse (NIDA)Not yet recruitingMethamphetamine-dependence | Methamphetamine Abuse
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
Centre for Addiction and Mental HealthNot yet recruitingMethamphetamine-dependence | Methamphetamine AbuseCanada
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
University of ArkansasCompletedCharacterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot StudyMethamphetamine Dependence | Methamphetamine WithdrawalUnited States
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States, Canada
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
Clinical Trials on Buprenorphine injection (BUP-Inj)
-
New York State Psychiatric InstituteSchering-PloughCompleted
-
Yih-Ing HserNational Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaboratorsNot yet recruitingSubstance-Related Disorders | Opioid-Related Disorders | Narcotic-Related DisordersUnited States
-
University of VermontUnknownOpioid-use DisorderUnited States
-
NYU Langone HealthHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsRecruitingOpioid Use Disorder (OUD)United States
-
Alkermes, Inc.National Institute on Drug Abuse (NIDA)Completed
-
National Institute of Allergy and Infectious Diseases...National Institute on Drug Abuse (NIDA)TerminatedHIV Infections | Opioid-Related DisordersChina, Thailand
-
University of Texas Southwestern Medical CenterNational Institute on Drug Abuse (NIDA)RecruitingCocaine Use DisorderUnited States
-
Hanlim Pharm. Co., Ltd.CompletedBreast DiseasesKorea, Republic of
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); University of California, San Francisco and other collaboratorsNot yet recruitingOpioid Use DisorderUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Heroin DependenceUnited States